EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy)

Xiao Huang, Huihui Bao, Congcong Ding, Junpei Li, Tianyu Cao, Lishun Liu, Yaping Wei, Ziyi Zhou, Nan Zhang, Yun Song, Ping Chen, Chongfei Jiang und 11 weitere

European Journal of Nutrition · 2024-08 · 63 (5) · 1513-1528

DOI: 10.1007/s00394-024-03344-8 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift European Journal of Nutrition, online erschienen am 13.03.2024. Verfasst von Xiao Huang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital, Jiangxi medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Folic Acid, Genotype, Homocysteine, Methylenetetrahydrofolate Reductase (NADPH2). Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, Key R&D Projects, Jiangxi, Key R&D Plan-Key Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While folic acid (FA) is widely used to treat elevated total homocysteine (tHcy), promoting vascular health by reducing vascular oxidative stress and modulating endothelial nitric oxide synthase, the optimal daily dose and individual variation by MTHFR C677T genotypes have not been well studied. Therefore, this study aimed to explore the efficacy of eight different FA dosages on tHcy lowering in the overall sample and by MTHFR C677T genotypes.

Methods

This multicentered, randomized, double-blind, controlled clinical trial included 2697 eligible hypertensive adults with elevated tHcy (≥ 10 mmol/L) and without history of stroke and cardiovascular disease. Participants were randomized into eight dose groups of FA combined with 10 mg enalapril maleate, taken daily for 8 weeks of treatment.

Results

The intent to treat analysis included 2163 participants. In the overall sample, increasing FA dosage led to steady tHcy reduction within the FA dosing range of 0–1.2 mg. However, a plateau in tHcy lowering was observed in FA dose range of 1.2–1.6 mg, indicating a ceiling effect. In contrast, FA doses were positively and linearly associated with serum folate levels without signs of plateau. Among MTHFR genotype subgroups, participants with the TT genotype showed greater efficacy of FA in tHcy lowering.

Conclusions

This randomized trial lent further support to the efficacy of FA in lowering tHcy; more importantly, it provided critically needed evidence to inform optimal FA dosage. We found that the efficacy of FA in lowering tHcy reaches a plateau if the daily dosage exceeds 1.2 mg, and only has a small gain by increasing the dosage from 0.8 to 1.2 mg. ClinicalTrials.gov Identifier NCT03472508 (Registration Date: March 21, 2018).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Folic AcidGenotypeHomocysteineMethylenetetrahydrofolate Reductase (NADPH2)AdultAgedFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugDouble-Blind MethodEnalaprilHyperhomocysteinemiaHypertension

Stichwörter der Autor:innen

Folic acidHomocysteineMTHFR C677T genotypesOptimal dosage

Substanzen

EnalaprilFolic AcidHomocysteineMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, human

Autor:innen und Institutionen

  • Department of Cardiology, The Second Affiliated Hospital, Jiangxi medical College, Nanchang University, Nanchang, China.
  • Center for Prevention and Treatment of Cardiovascular Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Biological Anthropology, University of California Santa Barbara, Santa Barbara, CA, USA.
  • Institute of Biomedicine, Anhui Medical University, Hefei, China.
  • Graduate School at Shenzhen, Tsinghua University, Shenzhen, China.
  • Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China.

Förderung

  • the National Natural Science Foundation of China
  • Key R&D Projects, Jiangxi
  • Key R&D Plan-Key Projects
  • the Jiangxi Provincial Health Commission
  • the Jiangxi Science and Technology Innovation Platform Project

Zitieren

APA

Huang, X., Bao, H., Ding, C., Li, J., Cao, T., Liu, L., Wei, Y., Zhou, Z., Zhang, N., Song, Y., Chen, P., Jiang, C., Xie, L., Qin, X., Zhang, Y., Li, J., Sun, N., Tang, G., Wang, X., …, & Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) Trial Investigators (2024). Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy). European Journal of Nutrition, 63(5), 1513-1528. https://doi.org/10.1007/s00394-024-03344-8

Vancouver

Huang X, Bao H, Ding C, Li J, Cao T, Liu L, et al. Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy). European Journal of Nutrition. 2024;63(5):1513-1528. doi:10.1007/s00394-024-03344-8

BibTeX
@article{Huang2024,
  author = {Huang, Xiao and Bao, Huihui and Ding, Congcong and Li, Junpei and Cao, Tianyu and Liu, Lishun and Wei, Yaping and Zhou, Ziyi and Zhang, Nan and Song, Yun and Chen, Ping and Jiang, Chongfei and Xie, Liling and Qin, Xianhui and Zhang, Yan and Li, Jianping and Sun, Ningling and Tang, Genfu and Wang, Xiaobin and Wang, Hong and Huo, Yong and Cheng, Xiaoshu and Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) Trial Investigators, Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) Trial Investigators},
  title = {Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy)},
  journal = {European Journal of Nutrition},
  year = {2024},
  volume = {63},
  number = {5},
  pages = {1513--1528},
  doi = {10.1007/s00394-024-03344-8}
}
Kostenlos starten →